Host cells expressing recombinant human erythropoietin
CA 2350335 C · Owner: Carcagno, Carlos Miguel · Inventors: Vidal, Juan Alejandro; Melo, Carlos; Carcagno, Carlos Miguel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The gene coding for human erythropoietin (EPO) was obtained from human genomic DNA. The gene used does not include sequences from regions at i 5' of the first translated ATG and ii 3' of the stop codon of the EPO gene. The gene was cloned into an expression plasmid for eukaryotic cells that have as sole expression control elements the early promoter of the SV40 virus and its polyadenylation signal. Recombinant cells resulting from transfection with genetic constructs used provide an unexpectedly high level of protein expression of 50 mg of recombinant EPO per liter of culture medium per day.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 8, 1999 and granted February 26, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 8, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 8, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.